Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel  Disease Patients Receiving Immunosuppressive Treatment in the  Pre-Vaccine Era

Eşkazan, Tuğçe; Aygün, Gökhan; Bakkaloğlu, Oğuz Kağan; Kurt, Enes Ali; Nohut, Okan Kadir; Candan, Selçuk; Önal, Uğur; Erzin, Yusuf; Hatemi, Ali İbrahim; Çelik, Aykut Ferhat

doi:10.14744/Jenterocolitis.2025.99310

Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era

Tuğçe Eşkazan¹ ,

Gökhan Aygün² ,

Oğuz Kağan Bakkaloğlu¹ ,

Enes Ali Kurt¹ ,

Okan Kadir Nohut³ ,

Selçuk Candan¹ ,

Uğur Önal¹ ,

Yusuf Erzin¹ ,

Ali İbrahim Hatemi¹ ,

Aykut Ferhat Çelik¹

¹Division of Gastroenterology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Türkiye
²Department of Infectious Diseases and Clinical Microbiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
³İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Fikret Biyal Central Research Laboratory, İstanbul, Türkiye

Journal of Enterocolitis 2025; 4(2): 48-48 DOI: 10.14744/Jenterocolitis.2025.99310

Full Text PDF

Eşkazan T, Aygün G, Bakkaloğlu OK, Kurt EA, Nohut OK, Candan S, Önal U, Erzin Y, Hatemi Aİ, Çelik AF. Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era. . 2025 ;4(2):48-48. doi: 10.14744/Jenterocolitis.2025.99310.

Eşkazan T, Aygün G, Bakkaloğlu OK, et al. Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era. . 2025;4(2):48-48. doi: 10.14744/Jenterocolitis.2025.99310

Eşkazan, T., Aygün, G., Bakkaloğlu, O. K., Kurt, E. A., Nohut, O. K., Candan, S., Önal, U., Erzin, Y., Hatemi, A. İ., & Çelik, A. F. (2025). Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era. Journal of Enterocolitis, 4(2), 48-48. https://doi.org/10.14744/Jenterocolitis.2025.99310

Eşkazan, T., et al. "Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era." Journal of Enterocolitis, vol. 4, no. 2, 2025, pp. 48-48. https://doi.org/10.14744/Jenterocolitis.2025.99310.

Eşkazan, T., et al. 2025. "Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era." Journal of Enterocolitis 4, no. 2: 48-48. https://doi.org/10.14744/Jenterocolitis.2025.99310.

Journal Display Format:

Authors: Tuğçe Eşkazan, Gökhan Aygün, Oğuz Kağan Bakkaloğlu, Enes Ali Kurt, Okan Kadir Nohut, Selçuk Candan, Uğur Önal, Yusuf Erzin, Ali İbrahim Hatemi, Aykut Ferhat Çelik
Article Title: Corrigendum:COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era
Journal Name: Journal of Enterocolitis
Year: 2025
Volume: 4
Issue: 2
Pages: 48 - 48
DOI: 10.14744/Jenterocolitis.2025.99310

RIS BibTeX EndNote Medlars